Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Hypertrophic Cardiomyopathy.
Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Gilead Sciences Inc
Heart Metabolics Ltd
Lead Discovery Center GmbH
miRagen Therapeutics Inc
MyoKardia Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hypertrophic Cardiomyopathy Overview 7
Therapeutics Development 8
Pipeline Products for Hypertrophic Cardiomyopathy - Overview 8
Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 9
Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 10
Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 11
Hypertrophic Cardiomyopathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hypertrophic Cardiomyopathy - Products under Development by Companies 15
Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 16
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 17
Gilead Sciences Inc 17
Heart Metabolics Ltd 18
Lead Discovery Center GmbH 19
miRagen Therapeutics Inc 20
MyoKardia Inc 21
Hypertrophic Cardiomyopathy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
eleclazine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HCM-2 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
LUS-1 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MGN-9103 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
MYK-461 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
perhexiline maleate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ranolazine ER - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule for Cardiac Hypertrophy - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Hypertrophic Cardiomyopathy - Dormant Projects 46
Hypertrophic Cardiomyopathy - Discontinued Products 47
Hypertrophic Cardiomyopathy - Product Development Milestones 48
Featured News & Press Releases 48
Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 48
Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy 48
Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day 49
Aug 31, 2016: Heart Metabolics Announces Initiation of Phase 2b Study of Perhexiline for Hypertrophic Cardiomyopathy 51
Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy 52
Jul 11, 2016: MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 53
May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 54
Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 55
Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 55
Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 56
Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 57
Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
List of Tables
Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Hypertrophic Cardiomyopathy - Pipeline by Gilead Sciences Inc, H2 2016 17
Hypertrophic Cardiomyopathy - Pipeline by Heart Metabolics Ltd, H2 2016 18
Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, H2 2016 19
Hypertrophic Cardiomyopathy - Pipeline by miRagen Therapeutics Inc, H2 2016 20
Hypertrophic Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Hypertrophic Cardiomyopathy - Dormant Projects, H2 2016 46
Hypertrophic Cardiomyopathy - Discontinued Products, H2 2016 47
List of Figures
Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Targets, H2 2016 23
Number of Products by Stage and Targets, H2 2016 23
Number of Products by Mechanism of Actions, H2 2016 25
Number of Products by Stage and Mechanism of Actions, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28
